CIK 0001393434 · Large accelerated filer
OCULAR THERAPEUTIX, INC
Sign in to watch- Ticker
- OCUL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 781-357-4000
- Business address
- 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
- Former names
- I-THERAPEUTIX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $799,174
- in 9 filings, $788K under 10b5-1 plans
Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-02 | Kaiser Peter Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +240,932 | 240,932 | ||
| 2026-01-02 | Saroj Namrata Chief Business Officer | Grant or award | +79,112 | 254,620 | ||
| 2026-01-02 | Saroj Namrata Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +240,932 | 240,932 | ||
| 2026-01-02 | Waheed Nadia Chief Medical Officer | Grant or award | +79,112 | 326,280 | ||
| 2026-01-02 | Waheed Nadia Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +240,932 | 240,932 | ||
| 2026-01-02 | Heier Jeffrey S. Chief Scientific Officer | Grant or award | +79,112 | 326,425 | ||
| 2026-01-02 | Heier Jeffrey S. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +240,932 | 240,932 | ||
| 2026-01-02 | Notman Donald See Remarks | Grant or award | +79,112 | 389,292 | ||
| 2026-01-02 | Notman Donald See Remarks | Grant or award · Stock Option (Right to Buy) | +240,932 | 240,932 | ||
| 2025-11-26 | Dugel Pravin See Remarks | Gift 10b5-1 | −49,754 | 0 | ||
| 2025-11-26 | Dugel Pravin See Remarks | Gift 10b5-1 | +49,754 | 300,115 | ||
| 2025-11-24 | Nayak Sanjay Chief Strategy Officer | Sale 10b5-1 | −1,878 | $12.04 | $23K | 277,860 |
| 2025-11-24 | Dugel Pravin See Remarks | Sale 10b5-1 | −19,530 | $12.04 | $235K | 3,157,960 |
| 2025-11-24 | Kaiser Peter Chief Development Officer | Sale 10b5-1 | −3,007 | $12.02 | $36K | 191,433 |
| 2025-11-24 | Heier Jeffrey S. Chief Scientific Officer | Sale 10b5-1 | −3,469 | $12.04 | $42K | 245,940 |
| 2025-11-05 | Saroj Namrata Chief Business Officer | Sale 10b5-1 | −25,865 | $10.74 | $278K | 174,135 |
| 2025-10-08 | Anderman Todd Chief Legal Officer | Sale 10b5-1 | −11,132 | $12.34 | $137K | 87,568 |
| 2025-10-02 | Kaiser Peter Chief Development Officer | Sale 10b5-1 | −9,653 | $11.03 | $106K | 194,440 |
| 2025-10-02 | Heier Jeffrey S. Chief Scientific Officer | Sale 10b5-1 | −10,502 | $11.04 | $116K | 249,409 |
| 2025-09-09 | Dugel Pravin See Remarks | Gift | −49,754 | 3,177,490 |
Page 4 of 8 · 158 trades